Reuters: FDA okays start of BrainStorm stem cell trial in ALS patients

TEL AVIV (Reuters) - BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS). [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/azgdFF-th34/story01.htm

Read More